PDF(Pubmed)
Abstract：
The primary objective of this study is to record the clinical outcomes of autologous conditioned plasma (ACP) for the treatment of knee osteoarthritis (OA) based on published literature. Multiple databases (PubMed, Embase, Web of Science and Scopus) were searched using terms for \"knee OA\" and the intervention \"ACP\" for articles published in English to January 4, 2024. All clinical studies using ACP for knee OA were included. Studies not utilizing ACP alone, i.e. used as an adjunct with other modalities or not focusing on the management of knee OA, were excluded. Five studies, three randomized controlled trials (RCTs) and two real-world post-market studies conducted in a clinical practice met the inclusion/exclusion criteria and were included in this study. All studies demonstrated statistically significant improvements in various patient-reported outcome measures (PROMs), however the studies performed in the clinical practice reported non-accomplishment of minimally clinically important difference (MCID). The results demonstrated the potential of ACP for management of knee OA, however the MCID was not achieved in real-world clinical settings. Thus, more adequately powered RCTs with longer follow-up as well as real-world post-market studies are warranted to establish long-term efficacy and justify routine clinical use, respectively, of ACP in patients suffering with knee OA.
摘要：
这项研究的主要目的是根据已发表的文献记录自体条件血浆（ACP）治疗膝骨关节炎（OA）的临床结果。多个数据库(PubMed,Embase,WebofScience和Scopus）使用“膝盖OA”和干预“ACP”的术语搜索了至2024年1月4日以英文发表的文章。包括使用ACP治疗膝关节OA的所有临床研究。不是单独利用ACP的研究，即用作其他方式的辅助或不专注于膝关节OA的管理，被排除在外。五项研究,在临床实践中进行的3项随机对照试验(RCT)和2项现实世界上市后研究符合纳入/排除标准,被纳入本研究.所有研究均表明，各种患者报告的结局指标（PROMs）均有统计学上的显着改善，然而,在临床实践中进行的研究报告未实现最小临床重要差异(MCID).结果证明了ACP治疗膝关节OA的潜力，然而,在现实世界的临床环境中没有达到MCID.因此，有必要进行更充分的RCT和更长时间的随访以及现实世界的上市后研究，以建立长期疗效并证明常规临床使用合理，分别,膝关节OA患者的ACP。
